| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| epigallocatechin gallate | aryl hydrocarbon receptor | small molecule | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | investigational | unknown |
| epigallocatechin gallate | dihydrofolate reductase, mitochondrial | small molecule | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | investigational | unknown |
| epigallocatechin gallate | dna (cytosine-5)-methyltransferase 1 | small molecule | NA | drugbank | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | investigational | inhibitor |
| epigallocatechin gallate | neutrophil elastase | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | phase 3 | unknown |
| epigallocatechin gallate | fatty acid synthase | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | phase 3 | unknown |
| epigallocatechin gallate | matrix metalloproteinase-14 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | phase 3 | unknown |
| epigallocatechin gallate | matrix metalloproteinase-2 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | phase 3 | unknown |
| epigallocatechin gallate | squalene monooxygenase | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Fibrosis Liver[MeSHID:D008103] |
NA | phase 3 | unknown |
| click here to return to the previous page | ||||||||